<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05615584</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL22_0072</org_study_id>
    <nct_id>NCT05615584</nct_id>
  </id_info>
  <brief_title>Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence</brief_title>
  <acronym>MRM-OREX</acronym>
  <official_title>Multiple Reaction Monitoring (MRM) Versus I 125 Radioimmunoassay (RIA) for the Quantification of Orexin-A/Hypocretin-1 Levels in Cerebrospinal Fluid: a Prospective Diagnostic Validation Study in Patients With Hypersomnolence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In humans, selective loss of orexin neurons is responsible for type 1 narcolepsy (NT1), or&#xD;
      narcolepsy with cataplexy, or orexin deficiency syndrome.&#xD;
&#xD;
      The International Classification of Sleep Disorders 3rd edition (ICSD-3) distinguishes&#xD;
      between hypersomnolence of central origin: NT1, narcolepsy type 2 (NT2), or narcolepsy&#xD;
      without cataplexy, and idiopathic hypersomnia (HI). These rare conditions are all&#xD;
      characterised by hypersomnolence (excessive daytime sleepiness, or excessive need for sleep),&#xD;
      which is the primary and often most disabling symptom. A level of ORX-A in cerebrospinal&#xD;
      fluid (CSF) (&lt;110 pg/mL) is a very sensitive and specific biomarker of NT1, currently&#xD;
      sufficient for the diagnosis of this condition. In contrast, ORX neurons are thought to be&#xD;
      intact in IH and NT2, and the pathophysiological mechanisms underlying these diseases remain&#xD;
      unknown. Thus, their diagnosis is based solely on clinical and electrophysiological criteria.&#xD;
&#xD;
      The objective of this project is to determine the validity of a mass spectrometric technique&#xD;
      for the determination of ORX-A in the cerebral spinal fluid of patients suffering from&#xD;
      hypersomnolence in comparison with the radioimmunoassay which is the reference technique.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 30, 2023</start_date>
  <completion_date type="Anticipated">October 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Orexin-A dosage by Multiple Reaction Monitoring Mass Spectrometry</measure>
    <time_frame>Day 1 (=day of inclusion)</time_frame>
    <description>Multiple Reaction Monitoring mass spectrometry for orexin-A dosage in cerebrospinal fluid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Orexin-A dosage by radioimmunoassay</measure>
    <time_frame>Day 1</time_frame>
    <description>Radioimmunoassay for orexin-A dosage in cerebrospinal fluid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Age of onset of hypersomnia symptoms</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of cataplexy</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of cataplexy</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average duration of cataplexy</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth sleepiness scale (ESS)</measure>
    <time_frame>Day 1</time_frame>
    <description>the score will be between 0 and 24, higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcolepsy severity scale (NSS)</measure>
    <time_frame>Day 1</time_frame>
    <description>the score will be between 0 and 57, higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypersomnolence severity scale (IHSS)</measure>
    <time_frame>Day 1</time_frame>
    <description>the score will be between 0 and 50, higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia severity index</measure>
    <time_frame>Day 1</time_frame>
    <description>the score will be between 0 and 32, higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iterative sleep latency tests (TILE)</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of the HLA allele DQB1*06:02</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Narcolepsy</condition>
  <condition>Idiopathic Hypersomnia</condition>
  <condition>Cataplexy</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quantitative mass spectrometry assay</intervention_name>
    <description>ORX-A determination by quantitative mass spectrometry</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 8 years&#xD;
&#xD;
          -  Complaint of hypersomnolence and suspected central hypersomnolence&#xD;
&#xD;
          -  Benefiting from a standardised assessment: clinical, biological and neurophysiological&#xD;
&#xD;
          -  Lumbar puncture necessary for the assessment&#xD;
&#xD;
          -  Sufficient cerebrospinal fluid taken for biological analysis (at least 1 ml)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to lumbar puncture&#xD;
&#xD;
          -  Secondary hypersomnolence&#xD;
&#xD;
          -  Refusal to participate in the study or refusal of the lumbar puncture&#xD;
&#xD;
          -  Adult protected by law, or subject deprived of liberty, by judicial or administrative&#xD;
             decision or patient under guardianship or curatorship&#xD;
&#xD;
          -  Subject not affiliated to the French social security system&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 26, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 7, 2022</last_update_submitted>
  <last_update_submitted_qc>November 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>orexin/hypocretin</keyword>
  <keyword>sleepiness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
    <mesh_term>Cataplexy</mesh_term>
    <mesh_term>Idiopathic Hypersomnia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

